Drug intelligence / Profile preview

PHYX-002

Development stage: Preclinical
Lead developer: Protagenic Therapeutics

Overview

PHYX-002 is a preclinical drug candidate that originated from Phytanix Bio's pipeline. It was acquired by Protagenic Therapeutics as part of an all-stock reverse merger transaction. This asset is one of five drug candidates being considered for development across multiple therapeutic areas, including neurology, psychiatry, obesity, urology, and inflammation. The former owners of Phytanix Bio, Alterola Biotech and EMC2 Capital, hold an irrevocable option to repurchase PHYX-002 and other related assets.

Beyond the preview

Go deeper on PHYX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHYX-002.

Explore the full profile